Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eisai CoESALF +18.47%76 Equity-to-Asset is 0.62 as of Mar. 2026, which is 2% above its 10-year median of 0.61. GuruFocus rates ESALF with a GF Score™ of 76/100 and a GF Value™ of $35.05 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Eisai Co ranks better than 52.04% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Eisai Co's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $5,665 Mil. Eisai Co's Total Assets for the quarter that ended in Mar. 2026 was $9,132 Mil.
Therefore, Eisai Co's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.62.
The historical rank and industry rank for Eisai Co's Equity-to-Asset or its related term are showing as below:
ESALF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.57 Med: 0.61 Max: 0.65
Current: 0.62
During the past 13 years, the highest Equity to Asset Ratio of Eisai Co was 0.65. The lowest was 0.57. And the median was 0.61.
ESALF's Equity-to-Asset is ranked better than 52.04% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs ESALF: 0.62
Eisai Co (OTCPK:ESALF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Eisai Co Equity-to-Asset Related Terms
Eisai Co Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Eisai Co's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Eisai Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eisai Co Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eisai Co's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Eisai Co's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Eisai Co's Equity to Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eisai Co (ESALF) has a Equity-to-Asset of 0.62 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Eisai Co and its competitors. This is near median its historical median of 0.61. Over the past decade, Eisai Co's Equity-to-Asset has ranged from 0.57 to 0.65. According to the industry distribution chart, Eisai Co ranks #483 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 48%.
Is Eisai Co's Equity-to-Asset too high?
Eisai Co's current Equity-to-Asset of 0.62 is near median its 10-year median of 0.61. Over the past 10 years, this metric has ranged from a low of 0.57 to a high of 0.65. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Eisai Co's value of 0.62 is 1.6% above this industry median. Based on the distribution chart, Eisai Co ranks #483 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Eisai Co has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eisai Co's Equity-to-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Eisai Co ranks #483 out of 1007 companies for Equity-to-Asset. This puts Eisai Co in the upper half of its industry. The industry median Equity-to-Asset is 0.61. Eisai Co's value of 0.62 is 1.6% above this benchmark. Historically, Eisai Co's own Equity-to-Asset has ranged from 0.57 to 0.65 over the past decade. While the company's 10-year median is 0.61 vs. the industry median of 0.61, Eisai Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eisai Co's current Equity-to-Asset of 0.62 is 1.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Eisai Co and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eisai Co's current Equity-to-Asset is 0.62, which is near median its own 10-year median of 0.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eisai Co stock overvalued right now?
Based on GuruFocus' analysis, Eisai Co (ESALF) is currently considered Modestly Undervalued. The stock's GF Value™ is $35.05, compared to a current price of $31.01 — trading 11.5% below its estimated fair value. The current Equity-to-Asset is 0.62, which is near median its 10-year median of 0.61 and 1.6% above the Drug Manufacturers industry median of 0.61. Eisai Co's overall GF Score™ is 76/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Eisai Co (ESALF), the current Equity-to-Asset is 0.62 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eisai Co (ESALF) Overvalued in 2026?
Based on GuruFocus' analysis, Eisai Co stock appears to be undervalued.
The current stock price of $31.01 is trading 11.5% below its estimated GF Value™ of $35.05.
GuruFocus considers Eisai Co to be Modestly Undervalued.
Key valuation signals for ESALF:
Equity-to-Asset: 0.62 (near median its 10-year median of 0.61)
GF Value™: $35.05 vs. price of $31.01 (11.5% below fair value)
Industry Position: 1.6% above the Drug Manufacturers median (#483 of 1007)
No single metric tells the full story. See the ESALF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of research and development, manufacturing, sales, import, and export of pharmaceuticals. The pharmaceutical business is categorized by region, including East Asia & Global South; Europe, Middle East, Africa, Russia, Oceania (EMEA); Americas; China; and Japan. The company also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived from its American pharmaceutical business, followed by its Japanese pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.
76GF Score
Get the complete analysis for ESALF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ESALF has been successfully added to your 
